Hepatitis

Intervention reduced infections, but not mortality; no improvement on other endpoints

Risk 40% lower with use among those with preexisting liver disease, study found

Goal of 30% reduction in serum creatinine in the absence of full response or HRS reversal

While study suggests treatment initiation did not differ by race, editorial expresses doubt

In small study of children with severe hepatitis, 93% of blood samples tested positive for AAV2

Health news and commentary from around the Web gathered by MedPage Today staff

Higher risks tied to both infected women and men

Health news and commentary from around the Web gathered by MedPage Today staff

New recommendations favor universal access to screening rather than risk-based approach

Other notable changes include new guidance on polio, MMR, hepatitis B, and pneumococcal vaccines

All-cause mortality rate significantly lower in treated versus untreated group

With 10% efficacy at 6 months post-treatment, a finite HBV treatment may be on the horizon

100% success rate even without the use of hepatitis B immunoglobulin

A roundup of news from the AASLD annual meeting